Activating mutations in one of the three RAS genes (HRAS, KRAS, and NRAS) are observed in 5–10% of patients with head and neck cancer, and HRAS mutations in particular are detected in > 50% of patients with head and neck cancer41. Here, NRAS is linked to head and neck cancer.